Want to see UTMD full AI Analyst Report?
UTMD Stock Chart & Stats
$67.14
$1.96(2.92%)
At close: 4:00 PM EDT
$67.14
$1.96(2.92%)
Day’s Range― - ―
52-Week Range$53.66 - $75.75
Previous Close$69.1
Volume63.16K
Average Volume (3M)15.88K
Market Cap
$223.54M
Enterprise Value$132.30
Total Cash (Recent Filing)$87.53M
Total Debt (Recent Filing)$195.00K
Price to Earnings (P/E)21.8
Beta0.52
Next Earnings
Oct 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.72%
Share Statistics
EPS (TTM)3.22
Shares Outstanding3,183,818
10 Day Avg. Volume20,525
30 Day Avg. Volume15,884
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)1.55
Price to Sales (P/S)4.81
P/FCF Ratio12.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilitySustained high gross and net margins show that UTMD retains meaningful economics in its regulated medical-device niches, supporting resilience against cost pressure and providing resources for product development and operations.
High-Quality Cash ConversionFree cash flow closely tracking net income indicates that reported profits convert efficiently into usable cash. This supports ongoing investment, shareholder returns, and financial flexibility without relying heavily on external funding.
Near-Debt-Free Balance SheetMinimal leverage materially reduces solvency and refinancing risk. The conservative balance sheet gives UTMD flexibility to manage healthcare demand changes, absorb operating pressure, and fund initiatives from a position of financial strength.
Bears Say
Multi-Year Revenue ContractionRepeated revenue declines indicate weakening demand, market penetration, or product momentum rather than a one-period fluctuation. Persistent contraction can reduce operating leverage and constrain the resources available for growth investments.
Declining Free Cash FlowAlthough cash conversion remains strong, shrinking free cash flow signals that the business is generating less surplus cash over time. If sustained, this could limit reinvestment capacity and reduce the cushion supporting distributions.
Softening Margins And ReturnsLower returns on equity and reduced historical EBIT and EBITDA margins suggest diminishing operating efficiency or weaker mix and pricing power. Continued erosion would weaken the benefit of UTMD’s otherwise strong profitability profile.
Utah Medical Products News
UTMD FAQ
What was Utah Medical Products’s price range in the past 12 months?
Utah Medical Products lowest stock price was $53.66 and its highest was $75.75 in the past 12 months.
What is Utah Medical Products’s market cap?
Utah Medical Products’s market cap is $223.54M.
When is Utah Medical Products’s upcoming earnings report date?
Utah Medical Products’s upcoming earnings report date is Oct 27, 2026 which is in 69 days.
How were Utah Medical Products’s earnings last quarter?
Utah Medical Products released its earnings results on Jul 23, 2026. The company reported $0.844 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Utah Medical Products overvalued?
According to Wall Street analysts Utah Medical Products’s price is currently Overvalued.
Does Utah Medical Products pay dividends?
Utah Medical Products pays a Quarterly dividend of $0.31 which represents an annual dividend yield of 1.72%. See more information on Utah Medical Products dividends here
What is Utah Medical Products’s EPS estimate?
Utah Medical Products’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Utah Medical Products have?
Utah Medical Products has 3,183,818 shares outstanding.
What happened to Utah Medical Products’s price movement after its last earnings report?
Utah Medical Products reported an EPS of $0.844 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.241%.
Which hedge fund is a major shareholder of Utah Medical Products?
Currently, no hedge funds are holding shares in UTMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Utah Medical Products Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.23%
12-Months-Change
Fundamentals
Return on Equity
1.72%
Trailing 12-Months
Asset Growth
3.12%
Trailing 12-Months
Company Description
Utah Medical Products
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and delivery departments and neonatal intensive care units. Key offerings include fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools for childbirth. For newborns, they provide respiratory hoods (DISPOSA-HOOD), umbilical vessel catheters (GESCO), silicone oral protection devices (PALA-NATE), and lumbar sampling kits (MYELO-NATE). Beyond maternity care, the company supplies blood pressure monitoring systems (DELTRAN PLUS), disposable peritoneal dialysis sets (DIALY-NATE), urinary drainage systems (URI-CATH), and feeding devices (NUTRI-CATH/NUTRI-LOK). They also manufacture HEMO-NATE disposable filters, various catheterization procedure trays, and DELTRAN disposable pressure transducers along with related accessories and molded parts. A substantial portion of UTMD's offerings targets women's health and gynecological interventions. This includes advanced electrosurgical solutions like the LETZ system for cervical lesion excision, paired with FINESSE+ generators and various specialized electrodes (loop, ball, needle), and FILTRESSE evacuators. They also provide laparoscopic instruments (Femcare line), including trocars and cannulae, alongside EPITOME and OptiMicro electrosurgical devices. Complementing these are products for surgical contraception (Filshie Clip), endoscopic irrigation (PATHFINDER PLUS), suprapubic catheterization, and urinary incontinence management (LIBERTY systems). Specialized tools for uterine assessment and sampling, such as the ENDOCURETTE and TVUS/HSG-Cath, as well as the LUMIN uterine manipulator for laparoscopic procedures, complete this extensive portfolio. UTMD's diverse product range serves various healthcare settings, including neonatal intensive care units, labor and delivery wards, women's health centers within hospitals, outpatient clinics, and physicians' offices. The company facilitates distribution through a combination of direct customer service and sales teams, independent consultants, and manufacturer representatives. Established in 1978, Utah Medical Products, Inc. maintains its headquarters in Midvale, Utah.
Technical Analysis
Ownership Overview
0.68% Insiders
17.04% Mutual Funds
28.38% Other Institutional Investors
40.58% Public Companies and
Individual Investors